- Company
- Hexaxim may be administered in general hospitals in Korea
- by Eo, Yun-Ho Jan 10, 2025 05:52am
- Hexaxim, a hexavalent combination vaccine for infants that was included in the National Immunization Program, may now be administered in general hospitals. According to industry sources, Sanofi Korea's Hexaxim prefilled syringe has now passed the drug committees (DCs) of 17 medical institutions nationwide, including Seoul National Univers
- Company
- Lilly Korea releases Ebglyss for atopic dermatitis in Korea
- by Whang, byung-woo Jan 10, 2025 05:52am
- Lilly Korea announced on the 9th that it had launched Ebglyss (lebrikizumab) in Korea for the treatment of moderate-to-severe atopic dermatitis.&160; Ebglyss is a novel biologic agent that selectively blocks cytokine interleukin (IL)-13, a major cause of atopic dermatitis. It was approved by the Ministry of Food and Drug Safety in Au
- Company
- Leclaza’s new trial data shows improved OS
- by Son, Hyung Min Jan 9, 2025 05:57am
- The Leclaza plus Rybrevant combination achieved statistically significant overall survival (OS) results. Johnson & Johnson expects Leclaza plus Rybrevant to extend OS by more than a year compared to Tagrisso monotherapy. The positive OS outcome for the combination strengthens its potential to become the first-line standard of care for EGFR-p
- Company
- Vabysmo approved for retinal vein occlusion macular edema
- by Whang, byung-woo Jan 9, 2025 05:56am
- Roche Korea announced on the 8th that Vabysmo has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. With the approval, Vabysmo is now approved for 3 indications in Korea, including as a treatment for ▲neovascular (wet) age-relate
- GC Biophara to offset Lipidil supra loss with new drug?
- by Lee, Tak-Sun Jan 9, 2025 05:56am
- As GC Biopharma successfully obtains reimbursement listing of a new product containing fenofibrate for treating hypertriglyceridemia, the industry closely watches its impact on shifting the competitive structure in the market. Lipidil supra containing fenofibrate is a product that GC Biopharma generated as a blockbuster drug after introdu
- Company
- Krazati receives orphan drug designation in Korea
- by Eo, Yun-Ho Jan 9, 2025 05:56am
- The second KRAS inhibitor 'Krazati' has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced the news through the first orphan drug designation announcement of the new year. Specifically, Krazati is indicated for 'locally advanced or metastatic non-small cell lung cancer (NSCLC) wit
- Policy
- AML treatment Mylotarg stalled at the DREC review
- by Lee, Tak-Sun Jan 9, 2025 05:56am
- The high price was found to be the reason Pfizer Korea's new drug Mylotarg (gemtuzumab ozogamicin), a treatment for acute myeloid leukemia (AML), did not pass the Health Insurance Review and Assessment Service (HIRA) stage. HIRA acknowledged the drug's improvement in clinical utility but did not approve its cost-effectiveness. According
- Company
- Wegovy vs Mounjaro in KOR…who's the winner?
- by Moon, sung-ho Jan 9, 2025 05:56am
- As more people are living with obesity in the world, obesity treatment is gaining popularity. According to the World Obesity Federation report, more than half of the world's population in 2035, 10 years from now, will be categorized as overweight or obese. South Korea is projected to have a similar rate. At the end of last year, Novo Nordisk'
- Company
- Sales of Flu drug Tamiflu did not fare so well last year
- by Nho, Byung Chul Jan 8, 2025 05:53am
- The oseltamivir-based flu treatment market, commonly represented by Tamiflu, is on a vertical decline after peaking in sales in 2023. The market for related preparations was valued at KRW 35.6 billion in 2023, the largest in 5 years. By 3Q 2024, the oseltamivir market posted sales of KRW 6.2 billion; even when the sales of the fourth q
- Company
- J.P. Morgan selects ADC and obesity as big deal keywords
- by Moon, sung-ho Jan 8, 2025 05:53am
- With the opening of the 'J.P. Morgan Healthcare Conference', which attracted much attention last year with domestic pharmaceutical and biotech companies announcing the achievement of 'big deals,’ approaching, attention is gathering on what results will be announced this year. The keywords of this year's event are glucagon-like peptide-1 (GLP
